{
    "2018-02-09": [
        [
            {
                "time": "",
                "original_text": "跨境并购、新药申请虽热闹，中国药企的制剂出口2017年表现却平平",
                "features": {
                    "keywords": [
                        "跨境并购",
                        "新药申请",
                        "制剂出口",
                        "中国药企",
                        "2017年"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "从中国第一到世界第一，中国药企还要走多远?",
                "features": {
                    "keywords": [
                        "中国药企",
                        "世界第一"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "[看好评级]医药生物行业2017年年报业绩前瞻：稳健增长 分化明显 重点关注优质成长与稳健价值",
                "features": {
                    "keywords": [
                        "医药生物",
                        "2017年",
                        "年报",
                        "稳健增长",
                        "优质成长",
                        "稳健价值"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "PD-1/L1申报大利好 恒瑞、信达、百济等获加速机会",
                "features": {
                    "keywords": [
                        "PD-1/L1",
                        "申报",
                        "恒瑞",
                        "信达",
                        "百济",
                        "加速机会"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "2018年，这些首仿药即将上市！",
                "features": {
                    "keywords": [
                        "2018年",
                        "首仿药",
                        "上市"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}